Li Xiu-Mao, Chen Ze-Hao, Wang Ke-Yi, Chen Jun-Nan, Yao Zhao-Nong, Yao Yu-Hong, Zhou Xiao-Wei, Lin Nong
Department of Orthopedics, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, Zhejiang Province, China.
Orthopedics Research Institute, Zhejiang University, Hangzhou 310009, Zhejiang Province, China.
World J Orthop. 2024 Jun 18;15(6):593-601. doi: 10.5312/wjo.v15.i6.593.
Mazabraud's syndrome (MS) is a rare and slowly progressive benign disease characterized by the concurrent presence of fibrous dysplasia of bone and intramuscular myxoma, and is thought to be associated with mutations of the gene. To date, only about 100 cases of MS have been reported in the literature, but its standard treatment strategy remains unclear.
We report two cases of MS in young women who underwent different treatments based on their symptoms and disease manifestations. The first patient, aged 37, received internal fixation and intravenous bisphosphonate for a pathological fracture of the right femoral neck, excision of a right vastus medialis myxoma was subsequently performed for pain control, and asymptomatic psoas myxomas were monitored without surgery. Genetic testing confirmed a gene mutation in this patient. The second patient, aged 24, underwent right vastus intermedius muscle myxoma resection, and conservative treatment for fibrous dysplasia of the ilium. These patients were followed-up for 17 months and 3 years, respectively, and are now in a stable condition.
Various treatments have been selected for MS patients who suffer different symptoms. The main treatment for myxomas is surgical resection, while fibrous dysplasia is selectively treated if the patient experiences pathological fracture or severe pain. However, given the documented instances of malignant transformation of fibrous dysplasia in individuals with MS, close follow-up is necessary.
马扎布劳德综合征(MS)是一种罕见的、进展缓慢的良性疾病,其特征为骨纤维发育不良和肌内黏液瘤同时存在,被认为与该基因的突变有关。迄今为止,文献中仅报道了约100例MS病例,但其标准治疗策略仍不明确。
我们报告了两名年轻女性MS患者,她们根据自身症状和疾病表现接受了不同的治疗。第一名患者,37岁,因右股骨颈病理性骨折接受了内固定和静脉注射双膦酸盐治疗,随后为控制疼痛切除了右侧股内侧肌黏液瘤,对无症状的腰大肌黏液瘤进行了监测,未进行手术。基因检测证实该患者存在基因突变。第二名患者,24岁,接受了右侧股中间肌黏液瘤切除术,并对髂骨纤维发育不良进行了保守治疗。这些患者分别随访了17个月和3年,目前病情稳定。
对于出现不同症状的MS患者,已选择了多种治疗方法。黏液瘤的主要治疗方法是手术切除,而如果患者发生病理性骨折或出现严重疼痛,则对纤维发育不良进行选择性治疗。然而,鉴于有文献记载MS患者中纤维发育不良发生恶变的病例,密切随访是必要的。